Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Augustin, H; Freibauer, C; Bayer, L; Lunglmayr, G; Tschurlovich, F; Kuber, W; Pummer, K.
Molecular markers and their prognostic impact in patients with advanced prostate cancer undergoing intermittent androgen suppression.
Prostate Cancer Prostatic Dis. 2006; 9(3):279-283
Doi: 10.1038/sj.pcan.4500883
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Augustin Herbert
- Co-Autor*innen der Med Uni Graz
- Pummer Karl
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Objective: Tumour features were evaluated during intermittent androgen suppression (IAS), and their prognostic impact on the first off-treatment time was analysed. Patients and methods: Twenty patients with advanced prostate cancer underwent three consecutive prostate biopsies during the first cycle, namely at the beginning of androgen deprivation, 8 months after continuous therapy and at the time of prostate-specific antigen (PSA) progression above 20 ng/ml. Biopsy specimens were immunohistochemically processed and analysed for the apoptotic index ( AI), Ki-67, p53 and Bcl-2 to investigate eventual changes over time. Correlations and regression analysis were performed to assess the prognostic significance of clinical and pathological parameters in predicting the first off-treatment time. Results: In contrast to the AI, p53 and Bcl-2, Ki-67 was the only marker that significantly changed over time ( P = 0.008). The first off-treatment time correlated significantly with pretreatment PSA ( r = -0.594; P<0.01), testosterone recovery time ( r = 0.590; P = 0.013) and biopsy grade ( r = -0.738; P<0.01); only the latter gaining an independent factor in the multivariate analysis ( P = 0.022). Conclusions: During IAS, Ki-67 was the only molecular marker that consistently changed over time. However, it did not correlate with off-treatment time that was predicted independently by the initial biopsy grade only. First off-treatment time was best predicted by clinical parameters and molecular markers from needle biopsies did not further contribute to a better patient selection.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Aged, 80 and over -
- Androgen Antagonists - therapeutic use
- Anilides - administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -
- Biopsy -
- Carcinoma - diagnosis
- Cell Proliferation -
- Gene Expression Regulation, Neoplastic -
- Goserelin - administration & dosage
- Humans -
- Male -
- Middle Aged -
- Neoplasm Staging -
- Nitriles -
- Prognosis -
- Prostatic Neoplasms - diagnosis
- Testosterone - blood
- Tosyl Compounds -
- Tumor Markers, Biological - analysis
- Withholding Treatment -
- Find related publications in this database (Keywords)
- prostate cancer
- intermittent androgen suppression
- oncogenes
- proliferation markers